Compare BridgeBio Pharma Inc (BBIO) vs Dicks Sporting Goods Inc (DKS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Dicks Sporting Goods Inc — how do they compare? BridgeBio Pharma Inc trades at $84.99 (market cap $16.36B), while Dicks Sporting Goods Inc trades at $202.7 (market cap $18.35B). The key difference: BridgeBio Pharma Inc and Dicks Sporting Goods Inc are close in size by market cap, and Dicks Sporting Goods Inc pays a 2.44% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | DKS | |
|---|---|---|
Market Cap | $16.36B | $18.35B |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $239.17 |
52-Week Low | $47.29 | $187.78 |
Enterprise Value | $18.14B | $25.14B |
Dividend Yield | — | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.64, down 1.22% on the day, with a bullish technical signal from moving averages and strong analyst support. Revenue surged to $502.08M in 2025, though net losses widened to -$724.93M, reflecting high R&D spending. Recent news highlights Q2 2026 earnings misses but revenue beats, driven by Attruby sales growth and three late-stage regulatory submissions expected by mid-2027.
Outlook remains optimistic with an 88% buy rating and $104.56 price target, but risks include persistent cash burn, high debt of $1.72B, and negative equity. Key catalysts are FDA decisions in 2027, with success potentially driving significant upside, though failure could exacerbate financial strain.
Dick's Sporting Goods (DKS) trades at $202.66, down 5.34% on the day, with a bearish technical signal despite recent earnings beats. The company maintains solid fundamentals with a 4.71% net income margin and 20.9% ROE, while analyst consensus remains strongly bullish with a $263.22 price target. Recent news highlights DKS as a value stock pick with accelerating sales growth, though the stock faces near-term technical pressure.
The outlook remains positive given strong analyst support and consistent earnings performance, but investors should monitor the bearish technical indicators and upcoming Q2 2026 earnings report on August 25th. Key risks include retail sector competition and potential margin pressure as revenue growth outpaces profit growth in 2026 projections.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Dicks Sporting Goods Inc
Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.
Read more on DKS →
